JP5640019B2 - 糖尿病及び肥満症を治療するためのプテロシン化合物の使用 - Google Patents

糖尿病及び肥満症を治療するためのプテロシン化合物の使用 Download PDF

Info

Publication number
JP5640019B2
JP5640019B2 JP2011548230A JP2011548230A JP5640019B2 JP 5640019 B2 JP5640019 B2 JP 5640019B2 JP 2011548230 A JP2011548230 A JP 2011548230A JP 2011548230 A JP2011548230 A JP 2011548230A JP 5640019 B2 JP5640019 B2 JP 5640019B2
Authority
JP
Japan
Prior art keywords
group
compound
pterocin
pharmaceutical composition
glucose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2011548230A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012515801A5 (https=
JP2012515801A (ja
Inventor
シュ・フェン−リン
リュー・シン−フワ
ウアン・ビイン−ジュアン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Tsing Hua University NTHU
Taipei Medical University TMU
DCB USA LLC
Original Assignee
National Tsing Hua University NTHU
Taipei Medical University TMU
DCB USA LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Tsing Hua University NTHU, Taipei Medical University TMU, DCB USA LLC filed Critical National Tsing Hua University NTHU
Publication of JP2012515801A publication Critical patent/JP2012515801A/ja
Publication of JP2012515801A5 publication Critical patent/JP2012515801A5/ja
Application granted granted Critical
Publication of JP5640019B2 publication Critical patent/JP5640019B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/11—Pteridophyta or Filicophyta (ferns)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
JP2011548230A 2009-01-26 2010-01-26 糖尿病及び肥満症を治療するためのプテロシン化合物の使用 Expired - Fee Related JP5640019B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14738209P 2009-01-26 2009-01-26
US61/147,382 2009-01-26
PCT/US2010/022129 WO2010085811A2 (en) 2009-01-26 2010-01-26 Use of pterosin compounds for treating diabetes and obesity

Publications (3)

Publication Number Publication Date
JP2012515801A JP2012515801A (ja) 2012-07-12
JP2012515801A5 JP2012515801A5 (https=) 2013-03-14
JP5640019B2 true JP5640019B2 (ja) 2014-12-10

Family

ID=42354647

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011548230A Expired - Fee Related JP5640019B2 (ja) 2009-01-26 2010-01-26 糖尿病及び肥満症を治療するためのプテロシン化合物の使用

Country Status (10)

Country Link
US (1) US8633252B2 (https=)
EP (1) EP2389171B1 (https=)
JP (1) JP5640019B2 (https=)
KR (1) KR101746867B1 (https=)
CN (1) CN102333528B (https=)
AU (1) AU2010206549B2 (https=)
CA (1) CA2749931C (https=)
NZ (1) NZ594236A (https=)
TW (1) TWI522109B (https=)
WO (1) WO2010085811A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160020472A (ko) * 2013-06-19 2016-02-23 액세스 비지니스 그룹 인터내셔날 엘엘씨 체중 관리의 지원을 위한 케토헥소키나제의 식물 기반 저해제
CN106831386A (zh) * 2015-12-04 2017-06-13 江西中医药大学 新型蕨素类化合物在治疗糖尿病的应用
CN105878220B (zh) * 2016-04-21 2019-02-05 广州市爱菩新医药科技有限公司 倍半萜类化合物在制备防治高血脂药物中的应用
CN107232497A (zh) * 2017-06-01 2017-10-10 河北农业大学 一种具有降血脂功能的膨化食品及其制备方法
US20220257532A1 (en) * 2017-06-16 2022-08-18 Korpharm Co., Ltd. Compositions containing pterosin compound and derivatives thereof active ingredients for prevention or treatment of degenerative brain diseases
CN108576355B (zh) * 2018-03-27 2021-11-09 百色学院 一种蕨菜多糖含片及其制备方法
CN110156738B (zh) * 2019-06-26 2023-01-03 中北大学 一种伊鲁烷型倍半萜反应中间体及天然产物的全合成方法
EP4260850A4 (en) * 2020-12-14 2024-10-16 GHPharm Co., Ltd. PHARMACEUTICAL COMPOSITION COMPRISING A PTEROSIN COMPOUND AND A DERIVATIVE THEREOF AS AN ACTIVE INGREDIENT, FOR THE PREVENTION OR TREATMENT OF A PKA-ASSOCIATED DISEASE
KR20260019211A (ko) 2024-08-01 2026-02-10 주식회사 지에이치팜 프테로신 d의 신규한 합성 방법

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4745104A (en) * 1985-04-15 1988-05-17 The Regents Of The University Of California Pseudopterosin and synthetic derivatives thereof
US4849410A (en) * 1985-04-15 1989-07-18 The Regents Of The University Of California Pseudopterosin and synthetic derivatives thereof
JPS63146839A (ja) 1986-12-11 1988-06-18 Toa Nenryo Kogyo Kk プテロシン系化合物を含んで成る制癌剤
JPH02237932A (ja) * 1989-03-10 1990-09-20 Yokichi Mochizuki 結石等の治療剤
US5439936A (en) * 1989-10-03 1995-08-08 The Regents Of The University Of California Method of treating certain tumors using illudin analogs
AU668818B2 (en) * 1993-04-07 1996-05-16 Taiho Pharmaceutical Co., Ltd. Thiazolidine derivative and pharmaceutical composition containing the same
DE69719544T2 (de) * 1996-12-12 2003-11-06 Banyu Pharmaceutical Co., Ltd. Pyrazolderivate
FR2777566B1 (fr) * 1998-04-15 2003-02-21 Synthelabo Derives d'azacycloalcanes, leur preparation et leur application en therapeutique
HU230253B1 (hu) * 2001-01-26 2015-11-30 Merck Sharp & Dohme Corp Peroxiszóma proliferátor-aktivált receptor (PPAR) aktivátor(ok) és szterin-abszorpció inhibitor(ok) kombinációi és alkalmazásuk vaszkuláris indikációk kezelésére
AR036237A1 (es) * 2001-07-27 2004-08-25 Bayer Corp Derivados del acido indan acetico, intermediarios, y metodo para su preparacion, composicion farmaceutica y el uso de dichos derivados para la manufactura de un medicamento
DE10142666A1 (de) * 2001-08-31 2003-03-20 Aventis Pharma Gmbh Verwendung von C2-substituierten Indan-1-ol-Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas
DE10142668A1 (de) * 2001-08-31 2003-03-20 Aventis Pharma Gmbh Verwendung von C2-substituierten Indan-1-on-Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas
US6797287B2 (en) * 2001-09-25 2004-09-28 Pharmachem Laboratories, Inc. Phaseolamin compositions and methods for using the same
BRPI0309689B1 (pt) * 2002-04-30 2021-06-29 Unigen, Inc Composições compreendendo uma mistura de flavonóides de anel-b-livre e flavanos e usos das mesmas
AU2003287965A1 (en) * 2002-10-24 2004-05-13 Carex Sa Modulation of peroxisome proliferator activated receptors activity
CA2505322A1 (en) * 2002-11-08 2004-05-21 Takeda Pharmaceutical Company Limited Receptor function regulator
JP4594611B2 (ja) * 2002-11-08 2010-12-08 武田薬品工業株式会社 受容体機能調節剤
FR2849849B1 (fr) 2003-01-13 2006-08-04 Merck Sante Sas Nouveaux acides carboxyliques et derives pour le traitement et la prevention du diabete et des dyslipemies
BRPI0407893A (pt) * 2003-02-26 2006-03-01 Unigen Pharmaceuticals Inc formulação para uso na prevenção e tratamento de doenças e condições induzidas por carboidrato
AU2004286857A1 (en) * 2003-11-04 2005-05-19 Merck & Co., Inc. Fused phenylalanine derivatives as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
US20050143350A1 (en) * 2003-11-19 2005-06-30 Seed John C. Combination drug therapy to treat obesity
PL1756084T3 (pl) * 2004-06-04 2009-06-30 Arena Pharm Inc Podstawione pochodne arylowe i heteroarylowe jako modulatory metabolizmu oraz profilaktyka i leczenie zaburzeń z metabolizmem związanych
EP1830804A2 (en) * 2004-12-06 2007-09-12 Reliant Pharmaceuticals, Inc. Stable compositions of fenofibrate with fatty acid esters
FR2880885B1 (fr) * 2005-01-14 2009-01-30 Merck Sante Soc Par Actions Si Derives d'acide phenylbenzoique, procedes pour leur preparation, compositions pharmaceutiques les contenant et applications en therapeutique
KR20070107108A (ko) * 2005-02-05 2007-11-06 아스트라제네카 아베 화학적 화합물
EP1924546A1 (en) * 2005-09-14 2008-05-28 Amgen, Inc Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders
WO2008089310A2 (en) * 2007-01-18 2008-07-24 Lexicon Pharmaceuticals, Inc. Delta 5 desaturase inhibitors for the treatment of obesity

Also Published As

Publication number Publication date
CN102333528B (zh) 2013-12-18
TW201039836A (en) 2010-11-16
AU2010206549A9 (en) 2016-08-25
EP2389171B1 (en) 2016-03-30
CA2749931C (en) 2018-03-06
KR20110125642A (ko) 2011-11-21
US20100190732A1 (en) 2010-07-29
NZ594236A (en) 2014-08-29
EP2389171A2 (en) 2011-11-30
AU2010206549B2 (en) 2016-08-25
WO2010085811A2 (en) 2010-07-29
KR101746867B1 (ko) 2017-06-14
EP2389171A4 (en) 2012-10-10
TWI522109B (zh) 2016-02-21
CA2749931A1 (en) 2010-07-29
US8633252B2 (en) 2014-01-21
JP2012515801A (ja) 2012-07-12
WO2010085811A9 (en) 2010-11-04
CN102333528A (zh) 2012-01-25
AU2010206549A1 (en) 2011-08-11

Similar Documents

Publication Publication Date Title
JP5640019B2 (ja) 糖尿病及び肥満症を治療するためのプテロシン化合物の使用
Alwan et al. Onco-immunity and therapeutic application of amygdalin: A review
KR20150014534A (ko) 폐암을 치료하기 위한 방법 및 조성물
EP1740212A2 (fr) Compositions pharmaceutiques contenant des derives de beta­carboline, et leur utilisation pour le traitement des cancers
US12102616B2 (en) Psilocin mucate
JPS6130521A (ja) 末梢神経障害の疼痛治療用ガングリオシド混合物
JP2025071293A (ja) ミトコンドリア障害を処置するための方法
KR20140102599A (ko) 뇌암 치료를 위한 방법 및 조성물
KR101695801B1 (ko) 운동 뉴런의 자가 포식 작용 억제를 위한 약학적 조성물 및 이의 용도
CN103804442B (zh) 黄酮醇衍生物及其医药用途
CN103585166B (zh) 黄醇酮衍生物的医药用途
CN114075256B (zh) 具有脂肪酶抑制活性的酰基他定类化合物、其制备方法及应用
CN103690535A (zh) 盐酸去亚甲基小檗碱在制备预防和/或治疗肝纤维化药物中的应用
CN114984128A (zh) 薯蓣总皂苷及其衍生物在制备铁死亡抑制剂药物中的应用
CN114748472B (zh) 丝裂霉素c在制备抗抑郁药物中的应用
WO2001055083A1 (en) Inositol derivatives and their pharmaceutical use
JP2006519752A (ja) 慢性骨髄性白血病を治療するために有用な医薬組成物
CN104546875A (zh) 三萜皂苷衍生物及其医药用途
WO2023165381A1 (zh) 具有脂肪酶抑制活性的酰基他定类化合物、其制备方法及应用
CN1678300A (zh) 可用于治疗慢性髓细胞性白血病的药物组合物
CN108272784A (zh) 丙酰胺类化合物在治疗肠道菌群紊乱相关疾病中的应用
JP2009100775A (ja) ジベレリンの調製および糖尿病での使用
TW200412941A (en) Use of abietic acid or derivative thereof for modulating permeability of plasma membrane

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130123

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130123

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140311

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140610

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140617

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140710

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140717

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140811

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20141007

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20141027

R150 Certificate of patent or registration of utility model

Ref document number: 5640019

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees